Instrument Inactif

Autres langues Apricus Biosciences Inc Nasdaq

Actions

US03832V1098

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

14/05	Seelos Therapeutics va procéder à un regroupement d'actions pour se remettre en conformité avec la Bourse	MT
14/05	Seelos Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	17/05
Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	16/05
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	14/05
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split	14/05
Seelos: Q1 Earnings Snapshot	14/05
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	03/05
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	29/04
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	29/04
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03
Seelos Therapeutics' ALS treatment fails in mid-stage study	19/03
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	29/01
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	26/01
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	26/01
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration	23/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Apricus Biosciences Inc Nasdaq

Actions

US03832V1098

Autres langues

Filtres